TD Cowen analyst Ryan Langston upgraded Enhabit (EHAB) to Buy from Hold with a price target of $12, up from $9. The firm cites an improving home health regulatory environment for the upgrade. Enhabit is heading into a positive earnings revision cycle given the “durability” of its volume growth, the analyst tells investors in a research note. It sees the company’s regulatory overhang as “de-risked.”
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on EHAB:
- Enhabit upgraded to Buy from Neutral at UBS
- Enhabit: Improved Regulatory Outlook, Discounted Valuation, and Offensive Capital Deployment Support Buy Rating and Higher $12 Target
- Enhabit initiated with a Hold at Truist
- Enhabit price target raised to $12 from $11 at Jefferies
- Enhabit, Inc to Present at 2025 Home Care Conference